Lindbrook Capital, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$74,987
+11.5%
1,963
+5.3%
0.01%
+14.3%
Q2 2023$67,271
+13.1%
1,865
+19.8%
0.01%0.0%
Q1 2023$59,462
-45.2%
1,557
-18.3%
0.01%
-46.2%
Q4 2022$108,451
+23.2%
1,906
-14.8%
0.01%
-13.3%
Q3 2022$88,000
-8.3%
2,237
+2.1%
0.02%
-6.2%
Q2 2022$96,000
+10.3%
2,191
+0.6%
0.02%
+23.1%
Q1 2022$87,000
-34.1%
2,178
-33.8%
0.01%
-35.0%
Q4 2021$132,000
+6500.0%
3,288
+7546.5%
0.02%
+1900.0%
Q3 2021$2,0000.0%430.0%0.00%
Q2 2021$2,0000.0%430.0%0.00%
Q1 2021$2,0000.0%430.0%0.00%
Q4 2020$2,000
+100.0%
430.0%0.00%
Q3 2020$1,0000.0%43
-23.2%
0.00%
Q1 2020$1,000
-92.9%
56
-94.4%
0.00%
-100.0%
Q4 2018$14,0001,0000.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders